REVOLUTION MEDICINES INC.

Revolution Medicines Inc. a clinical-stage precision oncology company develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630 an inhibitor of SHP2 which is in Phase 1/2 clinical trial for the treatment of solid tumors such as gynecologic tumors. It also develops RMC-5845 a selective inhibitor of SOS1 a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552 a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition the company is developing RMC-6291 a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236 a RAS-selective inhibitor of multiple RAS(ON) variants. Further it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors including RMC-4630. Revolution Medicines Inc. was incorporated in 2014 and is headquartered in Redwood City California.